Darapladib is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a key enzyme involved in the formation of atherosclerotic plaques. Darapladib-impurity is a byproduct of the synthesis of darapladib, which has gained significant attention in recent years due to its potential therapeutic and toxic effects. This paper aims to provide a comprehensive review of darapladib-impurity, including its method of synthesis or extraction, chemical structure and biological activity, biological effects, applications, future perspectives, and challenges.
Darapladib-impurity is synthesized as a byproduct of the synthesis of darapladib. The commonly used methods for the synthesis of darapladib include the condensation of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl bromide with 2,4-dichloro-5-methoxybenzoic acid, followed by deprotection of the acetyl groups. The yield of this method is around 50%, and the reaction requires several steps, including the use of toxic reagents such as bromine and thionyl chloride. Another method involves the condensation of 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl bromide with 2,4-dichloro-5-methoxybenzyl alcohol, followed by deprotection of the acetyl groups. This method has a higher yield of around 70%, but it also requires several steps and the use of toxic reagents. The extraction of darapladib-impurity from darapladib is also possible using various chromatographic techniques, such as reverse-phase high-performance liquid chromatography (RP-HPLC) and preparative thin-layer chromatography (PTLC). These methods have high efficiency and yield, but they also require the use of toxic solvents and generate hazardous waste.
Chemical Structure and Biological Activity
Darapladib-impurity is a structural isomer of darapladib, with a similar chemical structure but a different stereochemistry. It has been shown to have a similar mechanism of action as darapladib, inhibiting Darapladib-impurity activity and reducing the formation of atherosclerotic plaques. However, its potency is lower than that of darapladib, with an IC50 value of around 10 μM compared to 0.25 nM for darapladib. Darapladib-impurity has also been shown to have some cytotoxic effects on cancer cells, but its exact biological targets and mechanisms of action are still unclear.
The biological effects of darapladib-impurity on cell function and signal transduction are still poorly understood. Some studies have suggested that it may have some anti-inflammatory and anti-cancer effects, but more research is needed to confirm these findings. Darapladib-impurity has also been shown to have some potential therapeutic and toxic effects, depending on the dose and duration of exposure. In animal studies, it has been shown to reduce the formation of atherosclerotic plaques and improve cardiovascular function, but it has also been associated with some adverse effects, such as liver toxicity and gastrointestinal disturbances.
In medical research, darapladib-impurity has been used as a reference compound for the synthesis and characterization of darapladib. It has also been used in preclinical studies to investigate its potential therapeutic and toxic effects. In clinical trials, darapladib has been tested as a potential treatment for cardiovascular diseases, such as coronary artery disease and stroke. However, the results of these trials have been mixed, with some showing a reduction in cardiovascular events and others showing no significant benefit. Darapladib-impurity may also have some applications in environmental research, such as its role in pollution management and sustainability. In industrial research, it may be used in manufacturing processes to improve product quality and efficiency, but health and safety considerations must be taken into account.
Future Perspectives and Challenges
The current limitations in the use and study of darapladib-impurity include its low potency and unclear biological targets and mechanisms of action. Possible solutions and improvements include the development of more potent analogs and the use of advanced techniques, such as proteomics and metabolomics, to identify its biological targets. Future trends and prospects in the application of darapladib-impurity in scientific research include its potential use as a tool compound for the investigation of Darapladib-impurity biology and its role in cardiovascular diseases. However, more research is needed to fully understand its biological effects and potential therapeutic and toxic effects. Conclusion: Darapladib-impurity is a byproduct of the synthesis of darapladib, with a similar chemical structure and mechanism of action but lower potency. It has some potential therapeutic and toxic effects, depending on the dose and duration of exposure. Its applications in medical, environmental, and industrial research are still being explored, and future research is needed to fully understand its biological effects and potential uses.
Q1: How Can I Obtain a Quote for a Product I'm Interested In?
To receive a quotation, send us an inquiry about the desired product.
The quote will cover pack size options, pricing, and availability details.
If applicable, estimated lead times for custom synthesis or sourcing will be provided.
Quotations are valid for 30 days, unless specified otherwise.
Q2: What Are the Payment Terms for Ordering Products?
New customers generally require full prepayment.
NET 30 payment terms can be arranged for customers with established credit.
Contact our customer service to set up a credit account for NET 30 terms.
We accept purchase orders (POs) from universities, research institutions, and government agencies.
Q3: Which Payment Methods Are Accepted?
Preferred methods include bank transfers (ACH/wire) and credit cards.
Request a proforma invoice for bank transfer details.
For credit card payments, ask sales representatives for a secure payment link.
Checks aren't accepted as prepayment, but they can be used for post-payment on NET 30 orders.
Q4: How Do I Place and Confirm an Order?
Orders are confirmed upon receiving official order requests.
Provide full prepayment or submit purchase orders for credit account customers.
Send purchase orders to firstname.lastname@example.org.
A confirmation email with estimated shipping date follows processing.
Q5: What's the Shipping and Delivery Process Like?
Our standard shipping partner is FedEx (Standard Overnight, 2Day, FedEx International Priority), unless otherwise agreed.
You can use your FedEx account; specify this on the purchase order or inform customer service.
Customers are responsible for customs duties and taxes on international shipments.
Q6: How Can I Get Assistance During the Ordering Process?
Reach out to our customer service representatives at email@example.com.
For ongoing order updates or questions, continue using the same email.
Remember, we're here to help! Feel free to contact us for any queries or further assistance.
Note: Kindly utilize formal channels such as professional, corporate, academic emails, etc., for inquiries. The use of personal email for inquiries is not advised.
CHS-111 is a benzyl indazole compound which inhibits superoxide anion (O(2)(-)) generation. CHS-111 also reduced the fMLP- but not phorbol ester-stimulated PLD activity (IC(50) 3.9±1.2μM). CHS-111 inhibits the interaction of PLD1 with ADP-ribosylation factor (Arf) 6 and Ras homology (Rho) A, and reduces the membrane recruitment of RhoA in fMLP-stimulated cells.
2-[6-(4-Chlorophenoxy)hexyl]-1-cyano-3-pyridin-4-ylguanidine, also known as CPG-37157, is a small molecule compound that has gained significant attention in the scientific community due to its potential therapeutic and environmental applications. This paper aims to provide a comprehensive overview of the synthesis, chemical structure, biological activity, and potential applications of CPG-37157.
Chymostatin is a potent and selective inhibitor of chymotrypsin-like serine proteases. It was first isolated from Streptomyces sp. by Umezawa et al. in 1968. Since then, it has been extensively studied for its potential therapeutic and industrial applications.
CHZ868 or CHZ-868 is a potent and selective type II JAK inhibitor which demonstrates activity in JAK inhibitor persistent cells, murine MPN models, and MPN patient samples. CHZ868 showed significant activity in murine MPN models and induced reductions in mutant allele burden not observed with type I JAK inhibitors. CHZ868 stabilizes JAK2 in an inactive conformation. CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induced apoptosis in JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 alone. CHZ868 may be useful for patients with JAK2-dependent leukemias and other disorders.
CI-1002 is a novel anticholinesterase and muscarinic antagonist. The combined effect of AChE inhibition and muscarinic antagonism distinguishes PD 142676 from other anticholinesterases, and may be useful in treating the cognitive dysfunction of AD and produce fewer peripheral side effects.